In Vivo Non-Viral CAR-T Development Services

Currently, CAR-T therapy using ex vivo-generated cells poses multiple barriers associated, being complicated and expensive to manufacture, and with a high risk of toxicity. Therefore, in vivo CAR-T Cell Engineering is a potential solution with the ease of production and the possibility of standardization. Furthermore, studies have shown that in vivo CAR-T Engineering is associated with a reduced risk of the most common toxicities, such as CRS, and "on-target, off-tumor" toxicity.

Fig.1 Nano-delivery systems-driven CAR-T generation in vitro and in vivo. (Xin, et al., 2022)

Fig.1 Comparison of generating CAR-T in-vitro and generating CAR-T-in-vivo by nano-delivery systems.¹

Our In Vivo Non-viral CAR-T Cell Engineering Services

The rapid development of non-viral delivery systems has brought new perspectives to the design of in vivo CAR-T cell engineering. The non-viral delivery system has many advantages, its processing can take a variety of optimized formulations, and its synthesis is more streamlined, enabling precise drug delivery, reducing toxicity, and increasing the targeting of in vivo CAR-T therapeutics. Powered by years of experience in the CAR-T field, Creative Biolabs possesses strong capabilities in providing in vivo non-viral CAR-T Cell engineering services to facilitate customers' projects. There are some of our featured services as follows for reference, meanwhile, we also provide highly-customized in vivo non-viral CAR-T Cell engineering services to help global customers.

Featured services

In Vivo IVT mRNA-based CAR-T Cell Engineering

Creative Biolabs uses lipid nanoparticles (LNPs) to deliver mRNA encoding CAR in vivo. This method supports transient CAR expression, enabling in-body CAR-T generation without relying on viral systems or lengthy ex vivo manufacturing.

In Vivo Circular RNA-based CAR-T Cell Engineering

Creative Biolabs employs in vitro–transcribed circular RNA (circRNA) to deliver CAR constructs. circRNA lends prolonged stability and expression in vivo, enabling sustained CAR production in T cells without integrating into the genome.

In Vivo CAR-T Development with IVT saRNA Technology

Using self-amplifying RNA (saRNA) synthesized via in vitro transcription, Creative Biolabs programs CARs in T cells in vivo. SaRNA supports strong replication of the CAR-encoding transcript, reducing the required dosing while maintaining transient expression.

In Vivo CAR-T Development with LNP-DNA Technology

Creative Biolabs encapsulates plasmid DNA encoding CAR constructs into lipid nanoparticles and delivers them in vivo. This strategy provides transient CAR expression and avoids the use of viral vectors, reducing integration risk.

In Vivo CAR-T Development with PBAE Nanocomplex Technology

Creative Biolabs designs poly (βamino ester) (PBAE) nanocomplexes that compact CAR-encoding nucleic acids. These biodegradable polymer-based carriers promote efficient delivery to T cells in vivo and allow for targeted internalization and release.

In Vivo CAR-T Development with Lipid Nanoparticle Technology

Creative Biolabs leverages optimized lipid nanoparticle formulations to deliver different CAR-encoding payloads (mRNA, saRNA, DNA). These LNPs are tailored for in vivo T cell uptake, enabling CAR expression with a controlled, non-viral approach.

In Vivo CAR-T Development with Synthetic Nanocarrier Technology

Creative Biolabs develops custom-designed synthetic carriers (lipid or polymer-based) to deliver CAR constructs. These carriers are optimized for targeting, release kinetics, and payload compatibility to support safe, effective in vivo programming.

In Vivo CAR-T Development with Cas9-loaded Vesicle Genome Editing Technology

Creative Biolabs employs a Cas9-loaded vesicle displaying antibody fragments on its surface to selectively target T cells. This system delivers preassembled Cas9 nuclease-gRNA complexes and CAR transgenes for precise, non-viral in vivo genome editing.

In Vivo CAR-T Development with FuNVs (Fusion Nanovesicle) Technology

Creative Biolabs uses fusogenic nanovesicles (FuNVs) engineered to fuse with T cell membranes in vivo, delivering pre-expressed CAR proteins directly. This fusion-based method enables CAR-T cell generation without nucleic acid transfer.

Technology Platform

Our platform integrates cutting-edge mRNA and nanoparticle-based delivery methods to achieve highly efficient and controlled CAR expression in target T cells. Advanced formulations are carefully optimized to enhance cellular uptake, functional persistence, and bioavailability while reducing off-target effects and immune-related risks. The service covers the full spectrum of design, production, characterization, quality control, and in vivo validation, enabling researchers to seamlessly transition from early-stage discovery to robust preclinical studies with reproducible, high-quality results.

Package Service

We provide one-stop in vivo non-viral CAR-T cell engineering services to assist clients' projects, here are several prominent services you can refer to:

Published Data

Here are some results displaying the in vivo non-viral CAR-T cell engineering as a potentially ideal solution for tumor immunotherapy.

Frequently Asked Questions

Q1. Whether in vivo non-viral CAR engineering solution can be applied to other cells?

A: In vivo non-viral CAR-T cell engineering has many potential directions of application, such as in situ CAR-NK cells programming using the non-viral delivery system, in suit CAR-M cells programming.

Q2. What are the advantages of the non-viral approach comparing the viral-based approach for in vivo CAR-T engineering?

Types of Vector	Pros	Cons
Non-viral vector	Lipid-based nanoparticles	Simple manufacturing process	Low transfection efficiency
Polymer-based nanoparticles	High genetic cargo capacity	Toxicity related to materials
Inorganic nanoparticles	Low immunogenicity
Viral vector	Adenovirus	High transfection	Limited genetic cargo capability
Retrovirus	efficiency	Immunogenicity
Lentivirus	High stability of expression	Host genome integration

Professional consultation provides you with guidance throughout the entire project process, please contact us for a tailored solution.

Key Advantages

Why Choose Us

Non-viral CAR-T engineering offers enhanced safety and flexibility compared with viral approaches. Synthetic RNA or DNA-based carriers allow transient CAR expression without genome integration, reducing insertional risks. Nanoparticle-based delivery enables targeted T cell programming, lower immunogenicity, and potential for repeated dosing. Our platform simplifies manufacturing, supports rapid iteration, and is suitable for both preclinical research and translational development. Contact our team today to discuss your customized in vivo CAR-T project.

*1. In situ* CAR-T programming using synthetic DNA nanocarriers.**
2. In situ CAR-T programming using IVT mRNA nanocarriers.

Fig.2 Design and manufacture of IVT mRNA nanocarriers for in vivo CAR-T programming.²	Fig.3 In vitro cytotoxicity assay of nanoparticle-transfected T cells against Raji lymphoma cells.²